Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grapiprant + Eribulin in mIBC
NCT05041101Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of grapiprant in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2021; status: terminated.
02
Drugs
grapiprant
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05041101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041101.